Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The recent launch of Ebglyss, a new product in the market since December 2023, has already achieved over EUR 20 million in sales, primarily in Germany. Almirall is also making strides in R&D ...

The recent launch of Ebglyss, a new product in the market since December 2023, has already achieved over EUR 20 million in sales, primarily in Germany. Almirall is also making strides in R&D, with ...

The successful launch of Ebglyss® in the first markets in Europe generated €20.4 MM in the initial nine months of 2024, representing a 34% sales increase quarter-on-quarter. The potential of ...

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

and Ebglyss, supported by strategic R&D investments and expanded manufacturing. Despite a diversified portfolio and a promising pipeline, shares of the drug manufacturer dropped 6.3% after its Q3 ...

Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe atopic dermatitis. Patients had been previously treated with Dupixent ...

Eli Lilly and Company (LLY) - Yahoo Finance ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...